Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multiple Sclerosis Topic Center

Conference Coverage
Unmet Needs and the Evolving Treatment Landscape of Multiple Sclerosis
07/28/2021
Benjamin Greenberg, MD, MHS, discussed the unmet needs and upcoming developments in the diagnosis and treatment of multiple sclerosis (MS) during a virtual presentation given at Neurology Week.
Benjamin Greenberg, MD, MHS, discussed the unmet needs and upcoming developments in the diagnosis and treatment of multiple sclerosis (MS) during a virtual presentation given at Neurology Week.
Benjamin Greenberg, MD, MHS,...
07/28/2021
Neurology
Quiz
Is Depression Risk for Patients with Multiple Sclerosis Impacted by Disease Modifying Therapies?
07/27/2021
Is disease modifying therapy choice associated with subsequent risk of depression in MS?
Is disease modifying therapy choice associated with subsequent risk of depression in MS?
Is disease modifying therapy...
07/27/2021
Neurology
News
Choice of Disease Modifying Therapy May Impact Depression Risk for Multiple Sclerosis
07/23/2021
Choice of disease modifying therapy for patients with multiple sclerosis (MS) is associated with risk of depression, according to new research published in Multiple Sclerosis Journal.
Choice of disease modifying therapy for patients with multiple sclerosis (MS) is associated with risk of depression, according to new research published in Multiple Sclerosis Journal.
Choice of disease modifying...
07/23/2021
Neurology
News
High Efficacy Therapies Reduce Relapses in Secondary Progressive Multiple Sclerosis
07/23/2021
High-efficacy therapies are more effective at reducing relapse for patients with secondary progressive multiple sclerosis (MS) than low-efficacy therapies, according to new research published in Neurology.
High-efficacy therapies are more effective at reducing relapse for patients with secondary progressive multiple sclerosis (MS) than low-efficacy therapies, according to new research published in Neurology.
High-efficacy therapies are more...
07/23/2021
Neurology
Quiz
Quiz: Does Multiple Sclerosis Impact Mortality Risk of SARS-COV-2?
07/19/2021
According to a virtual presentation given at Neurology Week, does multiple sclerosis alone increase the risk of morbidity and mortality associated with COVID-19?
According to a virtual presentation given at Neurology Week, does multiple sclerosis alone increase the risk of morbidity and mortality associated with COVID-19?
According to a virtual...
07/19/2021
Neurology
News
Disease Modifying Therapies Improve Prognosis in Patients with Pediatric-Onset Multiple Sclerosis
06/25/2021
The risk of reaching persistent disability in patients with pediatric-onset multiple sclerosis (MS) has seen a significant reduction amidst increases of approved disease modifying therapies before age 18, which will continue to improve future...
The risk of reaching persistent disability in patients with pediatric-onset multiple sclerosis (MS) has seen a significant reduction amidst increases of approved disease modifying therapies before age 18, which will continue to improve future...
The risk of reaching persistent...
06/25/2021
Neurology
Quiz
Quiz: Which Is More Effective for Treatment of Multiple Sclerosis?
06/16/2021
According to results from a recent phase 3 trial, which treatment option is more effective at reducing the annualized relapse rate in patients with multiple sclerosis (MS)?
According to results from a recent phase 3 trial, which treatment option is more effective at reducing the annualized relapse rate in patients with multiple sclerosis (MS)?
According to results from a...
06/16/2021
Neurology
News
Intrathecal Immunoglobulin M Synthesis Predicts Disease Activity and Severity in Multiple Sclerosis
06/10/2021
Intrathecal Immunoglobulin M synthesis is a biomarker for disease activity and severity in patients with relapsing multiple sclerosis (MS), suggests results published in Annals of Neurology.
Intrathecal Immunoglobulin M synthesis is a biomarker for disease activity and severity in patients with relapsing multiple sclerosis (MS), suggests results published in Annals of Neurology.
Intrathecal Immunoglobulin M...
06/10/2021
Neurology
Have Scientists Used Artificial Intelligence to Detect and Treat Multiple Sclerosis?
05/24/2021
True or False: Scientists recently discovered three multiple sclerosis subtypes using artificial intelligence.
True or False: Scientists recently discovered three multiple sclerosis subtypes using artificial intelligence.
True or False: Scientists...
05/24/2021
Neurology
News
Scientists Identify Multiple Sclerosis Subtypes, Predict Progression and Treatment Response Using Artificial Intelligence
05/12/2021
MRI-based subtypes identified by unsupervised machine learning algorithms can be used to predict disease progression and response to treatment in patients with multiple sclerosis, according to findings from scientists at University College...
MRI-based subtypes identified by unsupervised machine learning algorithms can be used to predict disease progression and response to treatment in patients with multiple sclerosis, according to findings from scientists at University College...
MRI-based subtypes identified by...
05/12/2021
Neurology

Advertisement

Advertisement

News

Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
Anti-CD20 Therapies Do Not Slow Disability Worsening in Primary Progressive MS
News
Anti-CD20 Therapies Do Not Slow Disability Worsening in Primary Progressive MS
10/07/2024
Disability progression was no slower in patients with primary progressive multiple sclerosis (MS) treated with anti-CD20 infusion therapies than in untreated patients, according to a study of real-world patients published in Neurology.
Disability progression was no slower in patients with primary progressive multiple sclerosis (MS) treated with anti-CD20 infusion therapies than in untreated patients, according to a study of real-world patients published in Neurology.
Disability progression was no...
10/07/2024
Neurology
A woman sits on the couch with her arms wrapped around her legs, looking unhappy
News
Comorbidity Burden May Increase Disease Activity in MS Patients
09/30/2024
A higher comorbidity burden in clinical trial participants with multiple sclerosis (MS) was associated with an increased hazard of MS disease activity, according to study results published  in JAMA Neurology.
A higher comorbidity burden in clinical trial participants with multiple sclerosis (MS) was associated with an increased hazard of MS disease activity, according to study results published  in JAMA Neurology.
A higher comorbidity burden in...
09/30/2024
Neurology
a patient sits in a wheelchair
News
Phase 3 Studies Find Mixed Results for Investigational MS Drug
09/18/2024
An investigational drug for patients with multiple sclerosis (MS) yielded mixed results in a trio of phase 3 trials.
An investigational drug for patients with multiple sclerosis (MS) yielded mixed results in a trio of phase 3 trials.
An investigational drug for...
09/18/2024
Neurology
Elderly Patient With Doctor
News
Patients with Multiple Sclerosis Less Likely to Develop Alzheimer Disease
09/03/2024
Patients with MS had about half the rate of amyloid pathology compared with matched control subjects in the Washington University School of Medicine study.
Patients with MS had about half the rate of amyloid pathology compared with matched control subjects in the Washington University School of Medicine study.
Patients with MS had about half...
09/03/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Backward Walking Speed Reserve Reflects Disease Severity in Patients With MS
07/30/2024
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve,...
07/30/2024
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
Children Exposed to MS Drugs Through Breastfeeding Show No Developmental Harm
03/26/2024
Monoclonal antibodies taken for multiple sclerosis (MS) while breastfeeding appears not to affect a child’s development during the first 3 years of life, according to results from a preliminary study.
Monoclonal antibodies taken for multiple sclerosis (MS) while breastfeeding appears not to affect a child’s development during the first 3 years of life, according to results from a preliminary study.
Monoclonal antibodies taken for...
03/26/2024
Neurology
FDA headquarters
News
FDA Declines to Approve Application for Long-Acting Injection Targeting MS
03/13/2024
The US FDA has declined to approve glatiramer acetate depot 40mg (GA Depot 40), a long-acting investigational formulation of glatiramer acetate for the treatment of relapse-remitting multiple sclerosis (RRMS).
The US FDA has declined to approve glatiramer acetate depot 40mg (GA Depot 40), a long-acting investigational formulation of glatiramer acetate for the treatment of relapse-remitting multiple sclerosis (RRMS).
The US FDA has declined to...
03/13/2024
Neurology
News
In MS, Patients With Central Neuropathic Pain Carry Highest Emotional Burden
12/11/2023
Emotional burden and pain severity were greater in patients with multiple sclerosis (MS) who had central neuropathic pain than those who had musculoskeletal pain.
Emotional burden and pain severity were greater in patients with multiple sclerosis (MS) who had central neuropathic pain than those who had musculoskeletal pain.
Emotional burden and pain...
12/11/2023
Neurology
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement